Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (RBCC), today announced the collaboration of its latest target, Amarantus BioSciences, Inc. (OTCBB: AMBS), with Brewer Sports International (BSI) to increase awareness about new medical therapies in development to effectively treat traumatic brain injuries, commonly referred to as concussions, occurring primarily as a result of football and other contact sports.
The Coalition for Concussion Treatment campaign, known under its Twitter handle as #C4CT, has reached the critical milestone of 100 people signing a petition endorsing the movement and seeking to disseminate critical information about promising new therapies BSI will be identifying and raising awareness for over the next several months. Raising awareness of new advancement in developing treatments for TBI is critically important because it will allow the broader community to support drug developers’ efforts.
Recent research on concussions suffered by athletes of all ages, including children, is rapidly changing the public’s view of the impact these injuries have on players, including horrific side effects such as dementia and even suicide, as has been seen by the recent tragic deaths of certain current and former NFL and NHL players.
The newly formed Coalition for Concussion Treatment will focus on educating parents, players, fans and the sports community at large on the potential that new advances in developing new treatments for acute symptoms, as well as reducing the long-term negative impact of these devastating injuries have on the brain known as recovery of function. The sports community can have a meaningful positive influence on pushing new treatments in development forward.
AMBS is a biotech firm that has developed a therapeutic protein known as MANF to treat disorders associated with endoplasmic reticulum stress, including traumatic brain injury, Parkinson’s disease, Alzheimer’s disease and other afflictions. The firm is also working on a blood test designed to Parkinson’s disease and has teamed up with Banyan Biomarkers, the leader in the development of in vitro diagnostics for concussions, on a new treatment for TBI. Amarantus and Banyan expect to release an update from their work to the public shortly.
RBCC signed a letter of intent with AMBS earlier this week.
As awareness and concern spreads regarding the devastating health issues that can accompany concussions, the market for the diagnostic and treatment options being developed by AMBS is growing by the day. The Coalition for Concussion Treatment stands poised to drive increases in demand for these products. It was created to begin a viral campaign through Twitter and other digital and social media outlets to help ignite awareness of the severity of concussions and enhance treatment efforts.
Despite the growing rate of incidence of traumatic brain injuries, very few treatments and no cures are yet available. RBCC and AMBS plan to help change that.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc.(NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Patrick Brown, 813-367-9511
President and CEO
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here